Summary
The 503A Bulks List is an FDA-maintained list of bulk drug substances that licensed compounding pharmacies may use to prepare medications for individual patients with a valid prescription. Substances are evaluated through a structured process that can include review by the Pharmacy Compounding Advisory Committee (PCAC), and each is sorted into categories based on the available safety and characterization data. In 2023, the FDA placed 19 peptides into Category 2, which restricted their use in compounding. The PCAC meeting scheduled for July 23-24, 2026 will re-examine seven of these peptides in light of the available evidence. This is a complex regulatory process rather than a simple approval or ban, and the outcome will depend on how the evidence is weighed.
Why It Matters
Compounding pharmacy access matters because it is one of the primary legal pathways through which researchers and clinicians can obtain certain substances that are not available as FDA-approved drugs. When a substance is eligible for compounding under Section 503A, a licensed pharmacy can prepare it for an individual patient who holds a valid prescription. When it is not, those pathways narrow considerably.
The 2023 restrictions changed this landscape. By placing 19 peptides into Category 2, the FDA limited the ability of 503A pharmacies to compound them. Research suggests that interest in these compounds did not disappear; instead, the change increased demand for clarity about which substances would remain accessible and under what conditions. Compounding pharmacy groups and wellness practitioners argued that restricting regulated access could push individuals toward unregulated sources.
The July 2026 review is a significant moment in the regulatory history of peptides because it represents a structured, public re-examination of that 2023 decision. For researchers, the meeting is an opportunity to see how the current evidence is evaluated by an independent expert committee. The result could shape the legal status of several widely studied peptides for years to come.
Understanding Section 503A
Section 503A of the Federal Food, Drug, and Cosmetic Act establishes the conditions under which a licensed pharmacist or physician may compound a medication for an individual patient without the compounded product being treated as a new drug requiring FDA approval.
A 503A compounding pharmacy is a pharmacy that prepares customized medications for specific patients based on a prescription. Compounding can allow, for example, a different dosage form or the removal of an allergen, tailored to an individual need.
A compounded medication is not the same as an FDA-approved drug. An FDA-approved drug has been evaluated by the agency for safety and effectiveness for specific uses and is produced under approved manufacturing conditions. A compounded preparation is made for an individual patient and has not gone through that approval process.
The Bulks List exists because Section 503A generally requires that the bulk drug substances used in compounding either have an applicable monograph, be a component of an FDA-approved drug, or appear on a list the FDA develops. The 503A Bulks List is that developed list, and it governs which bulk substances may be used when the other conditions do not apply.
The valid prescription requirement means that compounding under 503A is tied to an individual patient and a prescriber. It is not a pathway for general manufacturing or over-the-counter sale.
How the Review Process Works
The path to the 503A Bulks List follows a defined sequence.
Step 1 - Nomination
The process begins when a substance is nominated to the FDA for consideration. Nominations can come from compounding pharmacies, industry groups, or other interested parties, and are expected to include supporting information about the substance.
Step 2 - FDA Evaluation
The FDA reviews the nomination and the available data, including safety, characterization, and the rationale for compounding use. Based on this initial assessment, the agency may sort the substance into a category.
Step 3 - PCAC Review
For substances that warrant independent expert input, the FDA may refer the question to the Pharmacy Compounding Advisory Committee. The PCAC examines the evidence in a public meeting and discusses whether the substance meets the criteria for the list. The July 23-24, 2026 meeting is an example of this step.
Step 4 - FDA Commissioner Decision
The PCAC issues a recommendation, but that recommendation is non-binding. The FDA Commissioner makes the final determination and may accept, modify, or reject the committee's advice.
Step 5 - List Update
If the FDA decides to include a substance, the Bulks List is updated accordingly. Inclusion permits compounding under a valid prescription; it does not constitute approval of the substance as a drug.
Category 1 and Category 2 Explained
During evaluation, nominated substances are sorted into categories that reflect the FDA's current assessment.
Category 1 substances are those under active evaluation that do not raise significant concerns at this stage, or that have been found to meet the criteria for inclusion. They may generally be used in compounding while review continues.
Category 2 substances are those the FDA has identified as presenting significant safety risks or as lacking sufficient evidence to support compounding use. They should not be compounded while under review.
In 2023, the FDA placed 19 peptides into Category 2, citing concerns about immunogenicity, toxicity risk, impurities, and limited human exposure data. In April 2026, the FDA published a Federal Register notice announcing that the PCAC would convene to re-examine several of these peptides. This signaled a willingness to revisit the earlier categorization through the committee's formal process. For the seven peptides now under review, the meeting offers a path for the available evidence to be re-evaluated, and a different categorization outcome would change how 503A pharmacies may handle them.
| Aspect | Category 1 | Category 2 |
|---|---|---|
| Compounding while under review | Generally permitted | Should not be compounded |
| FDA assessment | No significant concerns identified at this stage | Significant safety concerns or insufficient data |
| Typical basis | Adequate characterization and supporting data | Immunogenicity, toxicity, impurity, or exposure-data concerns |
| The 2023 peptides | Not applicable | 19 peptides placed here in 2023 |
How This Connects to the July 2026 Review
This explainer provides the background needed to understand the July 2026 PCAC meeting. The seven peptides scheduled for review - BPC-157, TB-500, KPV, MOTS-c, DSIP (Emideltide), Semax, and Epitalon - are among the substances placed into Category 2 in 2023. The meeting will examine whether the current evidence supports a different categorization.
A positive PCAC recommendation would advise the FDA Commissioner that one or more of these peptides could be considered for the 503A Bulks List. In practical terms, that could open a regulated pathway for licensed compounding pharmacies to prepare them for patients with a valid prescription. It would not mean the peptide is FDA-approved as a drug, and it would not establish it as safe or effective for any particular use.
For a detailed look at the meeting itself and each of the seven peptides, see the companion article, FDA Peptide Advisory Panel July 2026: What Researchers Need to Know. Because PCAC recommendations are non-binding and a second meeting is planned before February 2027, the full regulatory picture will continue to develop over time.
Related Peptides Under Review
The seven peptides scheduled for the July 2026 PCAC meeting each have a full research profile in the Pepvela library.
- BPC-157: Studied in preclinical research for tissue repair, including tendon, ligament, and gut mucosal healing.
- TB-500: A synthetic fragment related to Thymosin Beta-4, studied for actin regulation and tissue remodeling.
- KPV: A tripeptide fragment of alpha-MSH examined for anti-inflammatory activity in research models.
- MOTS-c: A mitochondrial-derived peptide studied for metabolic regulation and the response to exercise.
- DSIP (Emideltide): A delta sleep-inducing peptide studied for sleep architecture and HPA-axis context.
- Semax: A synthetic peptide related to an ACTH fragment, investigated for cognition and neuroprotection.
- Epitalon: A synthetic tetrapeptide studied in the context of telomere biology and longevity research.
Continue Your Research
References
- FDA Federal Register Notice -- April 15 2026 -- Pharmacy Compounding Advisory Committee Meeting
- Section 503A of the Federal Food Drug and Cosmetic Act -- fda.gov
- FDA -- Bulk Drug Substances That May Be Used in Compounding Under Section 503A
- OpenLoop Health -- "FDA PCAC Is Meeting to Review 7 Peptides July 2026" -- May 2026
- Meto -- "FDA July 2026 Peptide Meeting: What Patients Need to Know" -- April 2026